ClinicalTrials.gg
CompletedNCT03952091Updated Jul 3, 2024

TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

A Phase 3 interventional study of TJ202, Lenalidomide and Dexamethasone and Lenalidomide and Dexamethasone in Multiple Myeloma in Relapse and Refractory Multiple Myeloma, sponsored by TJ Biopharma Co., Ltd.. Completed at 41 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-07-03.

Sponsored by TJ Biopharma Co., Ltd. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
289
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 249 studies testing lenalidomide in Multiple Myeloma — 29 open to participants now, 70 under way, 14 of them phase 3. Lenalidomide · Multiple Myeloma.

Enrollment
36th of 249
289 · median 50
Started
2019
with 12 others
Phase 3
44 of 249
3 open now
Registered
186th of 249
by date

Among the 249 studies testing lenalidomide in Multiple Myeloma, this one is the 36th largest by enrollment, is one of 13 that started in 2019, is one of 44 in phase 3, and was the 186th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

29 of the 249 studies testing lenalidomide in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:

24 more — sign in →

By country, each count listing its studies:

All 29 open studies →

About lenalidomide

Lenalidomide: first FDA approval 2005 (REVLIMID), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 249 studies testing lenalidomide in Multiple Myeloma, or all of them as a file.
02

Study summary

A phase 3, randomized, open-label, parallel-controlled, multi-center study comparing TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in subjects with relapsed or refractory multiple myeloma who received at least 1 prior line of treatment

03

Conditions studied

  • Multiple Myeloma in Relapse
  • Refractory Multiple Myeloma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18, male or female;
  2. Subjects must have had documented MM;
  3. At the screening phase, subject must have one or more ;
  4. Subjects must have received at least 1 prior line treatment* for or refractor MM;
  5. Subjects who are in a state of progressive disease (PD);
  6. Subjects must have of no less than 6 months;
  7. Subjects must have an (Eastern Cooperative Oncology Group) performance status score of 0\~2;
  8. A woman of must have a negative serum pregnancy test within 14 days prior to the first study agent administration, and a negative urine pregnancy test on the day of the first study agent administration; as well as those should avoid sexual intercourse with the opposite sex or should adopt two reliable methods of at the same time during the study period. A woman of child-bearing potential is required to take effective contraceptive measures throughout this study and within 6 months after the last dosing; female subjects must agree not to donate any eggs for the purpose of assisted reproduction throughout this study and within 6 months after completion of this study;
  9. Male subjects who are sexually active with women of child-bearing potential and have not undergone vasoligation must agree to use barrier methods of birth control, or that their partners use block caps (cervical cap or dome cap), spermicidal foam, contraceptive gel, contraceptive diaphragm, contraceptive cream, or suppository, and all male subjects are not allowed to donate sperms throughout this study and within 6 months after the last dosing;
  10. Subject must sign an form (ICF) indicating that he or she understands the purpose of, and procedures required for, the study and is willing to participate in the study;
  11. Subject must be willing and able to adhere to the prohibitions and restrictions specified in this protocol.

Exclusion criteria

Exclusion Criteria:

  1. Subject has received anti-CD38 monoclonal antibody treatment previously;
  2. Subject has received CAR-T cell therapy previously;
  3. Subject has previously received allogenic stem cell transplant, or subject has received stem cell transplant within 3 months before administration of the study agent;
  4. Primary multiple myeloma;
  5. Subject's disease shows evidence of resistance to lenalidomide;
  6. Subject's disease shows evidence of intolerance to lenalidomide;
  7. Subject is exhibiting clinical signs of central nervous system (CNS) involvement of MM;
  8. Subjects with known moderate or severe persistent asthma within the past 5 years;
  9. Subject has active or C virus infection15. Subject is seropositive for (HIV);
  10. Subject has cardiac disease;
  11. Subject has known allergies, , or intolerance to lenalidomide, , monoclonal antibodies or human proteins, or their or known sensitivity to mammalian-derived products;
  12. Subject with known or suspicious conditions that would lead to failure to abide by the study protocol.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
289 participants (actual)

Study arms

  • Experimental
    TJ202, Lenalidomide and Dexamethasone

    Drug: TJ202, Lenalidomide and Dexamethasone

  • Active comparator
    Lenalidomide and Dexamethasone

    Drug: Lenalidomide and Dexamethasone

Interventions

  • DrugTJ202, Lenalidomide and Dexamethasone

    Drug pages: Felzartamab · Lenalidomide · Dexamethasone

    One dose of TJ202 will be given on Day 1 and Day 4 of Week 1, respectively, every week from Week 2 to Week 12, every 2 weeks from Week 13 to Week 24 and then every 4 weeks thereafter.Lenalidomide 25mg will be administered orally on Days 1 through 21 of each 28-days cycle.Dexamethasone 40 mg will be administered on Day 1 and Day 4 of Week 1, respectively and then 40mg weekly thereafter.

  • DrugLenalidomide and Dexamethasone

    Drug pages: Lenalidomide · Dexamethasone

    Lenalidomide 25mg will be administered orally on Days 1 through 21 of each 28-days cycle.Dexamethasone 40 mg weekly will be administered.

06

What researchers measure

Primary outcomes

  1. Progression-free survival (PFS)

    defined as the duration from the date of randomization to either PD, according to the IMWG criteria, or death, whichever occurs first

    Time frame: 18.4 months(Active) 30.7 months(experimental)

07

Study locations

41 sites
  • Capital Medical University (CMU) - Beijing Chao-Yang Hospital
    Beijing, Beijing 100020, China
  • Peking University Third Hospital
    Beijing, Beijing 100083, China
  • Capital Medical University (CMU) - Beijing Chao-Yang Hospital
    Beijing, Beijing, China
  • The First Affiliated Hospital of Bengbu Medical college
    Bengbu, Bengbu, China
  • The First Bethune Hospital of Jilin University
    Jilin, Changchun 130021, China
  • Hunan Cancer Hospital
    Hunan, Changsha, China
  • Fujian Medical University Union Hospital
    Fujian, Fuzhou 350001, China
  • The First Affiliated Hospital, Sun Yat-sen University
    Guangzhou, Guangdong, China
  • Sun Yat-Sen University Cancer Center
    Guangdong, Guangzhou 510060, China
  • Guangdong General Hospital
    Guangdong, Guangzhou 510080, China
  • Guangzhou First People's Hospital
    Guangdong, Guangzhou 510180, China
  • Nanfang Hospital
    Guangdong, Guangzhou 510515, China
  • The First Affiliated Hospital of Zhejiang University
    Zhejiang, Hangzhou 310003, China
  • The First Affiliated Hospital of Zhejiang University
    Zhejiang, Hangzhou, China
  • Hubei Cancer Hospital
    Wuhan, Hubei, China
  • Affiliated Hospital of Nantong University
    Nantong, Jiangsu, China
  • Chang Gung Medical Foundation - Kaohsiung Chang Gung Memorial Hospital
    Taiwan, Kaohsiung 833, China
  • The second affiliated hospital of Kunming medical university
    Yunnan, Kunming 650101, China
  • The First People's Hospital of Yunnan Province
    Yunnan, Kunming 650221, China
  • The First Hospital of Lanzhou University
    Lanzhou, Lanzhou 730000, China
  • Lanzhou University Second Hospital
    Lanzhou, Lanzhou 730030, China
  • Second Affiliated Hospital of Nanchang University
    Jiangxi, Nanchang 330006, China
  • Nanjing Drum Tower Hospital
    Nanjing, Nanjing 210008, China
  • Jiangsu Province Hospital
    Nanjing, Nanjing 210029, China
  • Guangxi Medical Univ. 1st Hospital
    Guangxi, Nanning 530021, China
  • Shanghai Changzheng Hospital
    Shanghai, Shanghai 200000, China
  • Shanghai Jiao Tong University School of Medicine - Ruijin Hospital
    Shanghai, Shanghai 200025, China
  • Shanghai Sixth People's Hospital
    Shanghai, Shanghai 200233, China
  • The First Hospital of China Medical University
    Shenyang, Shenyang 110001, China
  • Shenzhen Second Hospital
    Guangdong, Shenzhen 518035, China
  • The First Affiliated Hospital of Soochow University
    Suzhou, Suzhou 215006, China
  • National Taiwan University Hospital
    Taiwan, Taibei 100, China
  • Taichung Veterans General Hospital
    Taiwan, Taichung 40705, China
  • Tri-Service General Hospital
    Taiwan, Taipei 114, China
  • Tianjin Medical University General Hospital
    Tianjin, Tianjin 300052, China
  • Tianjin Cancer Hospital
    Tianjin, Tianjin 300060, China
  • The First Affiliated Hospital of Wenzhou Medical University
    Zhejiang, Wenzhou 325000, China
  • The Central Hospital Of Wuhan
    Hubei, Wuhan 430014, China
  • Sir Run Run Shaw Hospital Zhejiang University School of Medicine
    Hangzhou, Zhejiang, China
  • Henan Cancer Hospital
    Henan, Zhengzhou 450008, China
  • Taipei Veterans General Hospital
    Taipei, Taiwan
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2019 to primary completion in Jun 2024, 63 months.

Of 107 industry-sponsored phase 3 interventional studies under Multiple Myeloma, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 66. This study's 63 months is above that.

Counting every sponsor, half of 179 studies reached it within 55 months; a quarter within 34 and three quarters within 95.

How these figures are worked out, and which studies are left out of them.

Registered
May 14, 2019
First posted
May 16, 2019
StartActual
Mar 27, 2019
Primary completionActual
Jun 30, 2024
CompletionActual
Jun 30, 2024
Last update
Jul 3, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 3, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03952091
Lead sponsor
TJ Biopharma Co., Ltd.
Responsible party
Sponsor
First posted
May 16, 2019
Start date
Mar 27, 2019
Primary completion
Jun 30, 2024
Completion
Jun 30, 2024
Last update
Jul 3, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Felzartamab · Lenalidomide · Dexamethasone

Start the discussion